{"title":"Relapsed/Refractory Multiple Myeloma, DLBCL, and CLL: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner","authors":"Oxana Megherea, PharmD, BCOP","doi":"10.6004/jadpro.2023.14.6.11","DOIUrl":null,"url":null,"abstract":"Oxana Megherea, PharmD, BCOP, of the Hospital of the University of Pennsylvania, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. She also summarizes a subgroup analysis of elderly patients enrolled in the phase III POLARIX study and results of a phase III study of ibrutinib, obinutuzumab, and venetoclax vs. ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia.","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.6.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Oxana Megherea, PharmD, BCOP, of the Hospital of the University of Pennsylvania, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. She also summarizes a subgroup analysis of elderly patients enrolled in the phase III POLARIX study and results of a phase III study of ibrutinib, obinutuzumab, and venetoclax vs. ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
